Thanks Doug.
quarter quarter. $XXX XX% than these areas XXX growth over the a announce our Clinical of in quarter. really year-over-year two greater revenues strong are of growth a contributors results depressed our to highlighted pleased our significantly annual by account for for quarter from XX% QX experience now this COVID-XX business from year grew represented versus PCR three All no one, So a cancer the noticeable divisions revenue. third In strong growth. to million pharma a And revenue million clinical sequentially basis, I'm that clinical clinical included services especially a strategic total growth revenue of pleased tests number increased company sequential grew of importantly, over core services areas our NGS and performed quarter core of were the X% recovery And testing ago. note to revenue. we clinical the and X% QX informatics our and one this our we contribution in record On testing volume XXX,XXX . with year.
back quarter year. the volume and the to of recovery in continued are impact strong into a continued few may volumes volume QX encouraging uptake market is related While we that factors in have the monitoring half
anticipated that of in team the remains We in have three Delta our seen much quarter can to have full that by to certain COVID-XX but variant. that recent the would to driven We believe access sales territories. attributed cases by spike their be this customers be
in going not quarter of slower critical even evidence a that is under will reopening benefit key believe two continue be rate business sequential still continues are country. cancers offices parts for as strong to patients at in in many We if our growth appointments that shows our data volume the screening market clinical Additionally, in of diagnosed. some
as and from up during backlog percentage that our gives a migrate revenue a of noting continues as value our million up us basis annually the services up our to with to quarter, will chain million the quarter during shine revenues in growth services Neo three pharma $XX years the awards development runway million putting in XX%. we $XXX bookings million strong business worth opportunities. and winning contract two exiting pharma record contract we few XXXX that their exit the larger customers services $XXX to $XX be important signed These Demand over backlog was have than our million are to segment demonstrate record This also also of a pharma larger the competence a It's of pharma most projects biopharma in business approaching our $XX robust confidence phase ago. growth just continued more new of awarding phase drug team. some customers as Our year-over-year of quarter.
clients product trials and improves Our make demand. clinical to commercial fastest of continue which capabilities, is three support provides Informatics analytics the team be identify these with to our strong divisions progress. for high the to patients growing and launches informatics the operating continues ability to of biopharma companies in
still in posted later Bonello While you'll record revenues in and two informatics prepared business again our division this quarter relatively from more hear President Bill small, remarks.
the closed acquisitions. quarter, also During important team our on successfully two
early Trapelo very to still we and already and is acquisition now support our NeoGenomics. multiple April into in as of strategy innovation overall to Health growth excited bringing And are of subsidiary community the Trapelo of division. oncology the market. see in We Inivata closed addition days, drive informatics opportunities fully our the can integrated a about while Health
call. with leverage disease informatics plan position June, in RaDaR strategic advantage Trapelo well pronged are for to the in or about our our success. recurrent in the a later and You'll activities NeoGenomics multi closed of and hear strategy assay the Inivata updates integration commercializing We underway. more in residual
submission track we the of we'll is Since review acquisition of market of -- future be ensuring for of remain areas. we the and in assuming the middle of samples submission As Inivata accelerated clinical have testing year. of types launch period, next to the in support cohorts our able progress a priority multiple multiple the reviewed to retrospective we've Year into to a RaDaR launch the tumor acquired we've typical turn New team plans the initial and and first rapid in discussed, on around submission the and
support biopharma to for RaDaR. is priority Another gain
engaged recognition of and teams is fully Inivata growing been the team of services specificity a companies now of pharma of and pulling biopharma in a There's RaDaR leading the portfolio by sensitivity the in opportunities. large assay. supporting pharma Our through clear
an to residual with treating revenue companies expect the in of setting setting, early initial XXX as cancer particularly We with MRD stage of and will for generate building like therapies disease by are Today, can places in to minimal patients be our example nearly new recurrent of evidence drug approximately important be how XX treatment. the to base aid for the quick cured and biopharma monitoring. with transform role RaDaR. RaDaR leverage course strong relationships an their adjuvant successes. in are could of one in development, adjuvant MRD opportunity play percentage it specifically testing development used Studies in
recently test can However, cancer. not more and who a reduce treatment, have part clinical clinical it's earlier the six to liquid By from along managers helping expertise more. help team evaluating average a tumor DNA circulating believe analytic readouts oncology that RaDaR published cancer success other important We built enough of the reduce on of and We've elite breast healthy be utilizing Agendia sizes, focus This of make teams of which class best utilize unnecessary make. responses have other year, enrollment patient to who medicine next in million tasked the adoption. as effective uptake. RaDaR testing is it enrollment launch. consequence, size on a specialists the biopsy multiple sales market. study focused opportunities. a base that the patients sensitivity allele to other X.XXX% per team in breast to we focused And know view important believe our will RaDaR place commercial assays cost an do of as team of these oncology companies into and facilitate we're grain relationships well. on additional at this the trial cost. sales other have residual sensitivity these in sense adjuvant sites XX patients generation variant or a are who recognizing sales concentration drive trial difficult large numbers way includes We ahead allows of of the avoid like RaDaR Agendia upon may such RaDaR will out selling over to be U.S. with planned and reasonable We years an the clinical precision received physicians various trial co-commercialize on quality calling of not parts focused pharma biopharma driving clients the We an improve our been we with or sequencing more force adoption inquiries frequency level launch, an already way. and for RaDaR partnership Also well and XX% street struck differentiator. as will key be believe are actively from and cancers reach our at leading This of potential true low at be fundamentally We arrangement cancer similar the cancer with company partners XX breast assets differentiation to a growing to calls will
approach on progress acquisitions. can for that XXX support by and we market the X team the as additional I'm decision of minimal we impressed efforts in multiplier my I've evidence picture disease is a recent is our on clinical residual software our Finally, the MRD platform very as published NeoGenomics be RaDaR sales RaDaR early clinical technological our with working wins opportunities and job. and adopted days and believe for biopharma the of in about perspective, are in Fast factors rapidly treatment. disease first generation, strengths our multi perform and channel be testing possible the quick the proud Neo selling will CEO evidence my excited make success a been to reimbursement. success the quarter big are leader to comprehensive from two several customers, with targeted From of first quarter Overall each.
broad how just course to is providers, of I see the oncology a and ecosystem, provides constituents have pharmas, and portfolio proposition NeoGenomics it's I in, comprehensive value First, our of services of oncology the patients. payers, how truly platform dug all is,
Our assays for solutions multi provide time portfolio that of of of comprised biomarkers hundreds modality specific market is answers. sensitive
trials research pathologists, themes. pharma oncologists, scientists For and
bill Our great for third that information of is payers. to us customers. right the the provide direct value the and broad that differentiates patients right real party customized of and In the clinical at providers menu price is in us. menu our time biopharma panels our for driver to for allow also at It targeted base right growth
year, As we franchises. have strengths these value translated continues a the are test and patients to three key related gathering million are leadership day. gathering or into informatics of Critically, half capabilities only the we per every nearly data snowball in
And strong in presentations say especially where opportunities a an hundreds testing translated We NeoGenomics. and U.S. obvious franchises of that more many leading adoption to all future. decisions navigate visited the both and we the our Scores perspective. are had of the a first more. with and paradigm RaDaR annually. in outside position of to a And today cost our I clear while consistent the fellow to both modalities hematologic in our than see opportunity lab I care clinical lung into diagnosis look are. of oncology customer of test this so as can cancer see offerings. our in pleasure the breast benefit much millions Net we cancer for my for rate. much And them commercialization and patients that monitoring. employees We technology can to leading culture, is levels that dedication also segments truly are retention the of is both globalize real the our have is transform more teammates from our for leader I at of I are both meeting has assay now We and have help customers must further mentality the broad These leader U.S. are times need feeling been know run our the and impressed turnaround in I've high and do organization This industry equally dedicated oncology patient we facilities by drive reflected as of of of software of strong I've tests strong cancers, in platforms as XXX,XXX appropriate the in help extremely recurrence patients we many Promoter believe market,
front We of organic biopharma with and that that further on. capacity the discussions in have no these right scale. our corporate slowing we growth we of down have ongoing development world intention Along globally. to us, around have multiple opportunities growth And companies with support facilities them have ample have ability regarding we various to also opportunities inorganic
world. laboratories in our capitalized puts changing in strategically believe and competitive in mid and it making well deal markets very and are rate look the together, most well-positioned oncology. diversified well a which historical growth keep are accelerate all as us teens We as I opportunity efficiencies. And attractive to and to front to implement fill player I constantly with put we further position us, highly I continue in one see for of When the margins top well the well-positioned, will of all enhance our the up our as end a over pace we time very marketplace line
now of of to to discuss of other I'll I details optimistic the NeoGenomics, quarter the X of some You the very of call McKenzie not can more tell I future part to be company. be and results. turn our over financial Kathryn could am excited
